LUF6096 is a potent allosteric enhancer of adenosine A3 receptor. LUF6096 displays low orthosteric affinity for any adenosine receptor. LUF6096 has protective effects in myocardial ischemia/reperfusion injury.

Physicochemical Properties

Molecular Formula	C22H21CL2N3O
Molecular Weight	414.33
Exact Mass	413.106
CAS #	1116652-18-6
Related CAS #	1116652-18-6;
PubChem CID	25191023
Appearance	Typically exists as solid at room temperature
LogP	6.875
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	4
Heavy Atom Count	28
Complexity	528
Defined Atom Stereocenter Count	0
SMILES	ClC=1C=CC(=CC1Cl)N=C2NC3=CC=CC=C3C(=C2)NC(C4CCCCC4)=O
InChi Key	UWEIQVQNNLVOEI-UHFFFAOYSA-N
InChi Code	InChI=1S/C22H21Cl2N3O/c23-17-11-10-15(12-18(17)24)25-21-13-20(16-8-4-5-9-19(16)26-21)27-22(28)14-6-2-1-3-7-14/h4-5,8-14H,1-3,6-7H2,(H2,25,26,27,28)
Chemical Name	N-[2-[(3,4-Dichlorophenyl)amino]-4-quinolinyl]-cyclohexanecarboxamide
Synonyms	LUF6096 LUF 6096LUF-6096CF-602 CF602 CF 602
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	The dissociation rate of 125I-AB-MECA from A3 receptors in CHO cell membranes is halved by 2.5 times with LUF6096 (10 μM; 30-120 minutes) [1]. Forskolin-stimulated cAMP generation in CHO cells can be inhibited and the intrinsic activity of Cl-IB-MECA considerably enhanced by LUF6096 (10 μM; 15 min pretreatment) [1].
ln Vivo	In dogs, myocardial ischemia/reperfusion damage is prevented by LUF6096 (two intravenous bolus doses of 0.5 mg/kg or a single intravenous bolus dosage of 1 mg/kg) [1].
Animal Protocol	Animal/Disease Models: Adult mongrel dogs (15-25 kg) underwent left anterior descending (LAD) coronary artery occlusion and reperfusion [1] Doses: Two intravenous (iv) (iv)bolus injections of 0.5 mg/kg or a single intravenous (iv) (iv)bolus of 1 mg/kg given Medication: intravenous (iv) (iv)bolus Experimental Results: Infarct size was Dramatically diminished (approximately 50% reduction) compared to vehicle-treated dogs.
References	[1]. Heitman LH, et, al. A series of 2,4-disubstituted quinolines as a new class of allosteric enhancers of the adenosine A3 receptor. J Med Chem. 2009 Feb 26;52(4):926-31. [2]. Du L, et, al. Protection from myocardial ischemia/reperfusion injury by a positive allosteric modulator of the A₃ adenosine receptor. J Pharmacol Exp Ther. 2012 Jan;340(1):210-7.

Solubility Data

Solubility (In Vitro)

DMSO : ~20 mg/mL (~48.27 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2 mg/mL (4.83 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.4135 mL	12.0677 mL	24.1354 mL
	5 mM	0.4827 mL	2.4135 mL	4.8271 mL
	10 mM	0.2414 mL	1.2068 mL	2.4135 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.